Alzheimers Disease Patients Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Onset Type (Late onset disease, Early Onset Disease); Drug Class (Cholinergic, Memantine, Combined Drug, AChE inhibitors, Immunoglobulins); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales) and Geography

Report Code: TIPRE00019571 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

Alzheimers disease patients are the group of patients living with Alzheimers disease. Alzheimers disease is a progressive neurologic disorder that causes brain atrophy and brain cells to die. Alzheimers is the most common type of dementia which causes changes in social and physiological behavior of patients. Alzheimers generally occurs in mid-60s i.e. late onset disease. The agents which are used to treat Alzheimers patients include, cholinergic agents, immunoglobulins, combination therapy etc.

MARKET DYNAMICS

The Alzheimers disease Patients market is expected to grow in the forecast period owing to factors such as, increasing pool of patients with Alzheimers disease, rising geriatric population, increasing prevalence of neurologic disorders. Additionally, R&D activities by drug companies to launch and develop drug therapies is also expected to boost market growth. Whereas, high cost of medicine, potential side effects from treatment are expected to restrain market growth during forecast period.

MARKET SCOPE

The "Alzheimers Disease Patients Market" is a specialized and in-depth study of the Pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Alzheimers disease Patients market with detailed market segmentation by onset type, drug class, distribution channel. The Alzheimers disease Patients Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Alzheimers disease Patients Market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The Alzheimers disease Patients Market is segmented on the basis of onset type, drug class and distribution channel. On the basis of onset type the market is segmented as, late onset disease, early onset disease. On basis of drug class the market is segmented as, cholinergic, memantine, combined drugs, ACHE inhibitors, immunoglobulins. And on the basis of distribution channel the market is segmented as, hospital pharmacy, retail pharmacy and online sale.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Alzheimers disease Patients Market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Alzheimers disease Patients Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Alzheimers Disease Patients Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Alzheimers disease Patients Market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Alzheimers disease Patients Markets organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Alzheimers disease Patients Market are anticipated to have lucrative growth opportunities in the future with the rising demand for, Alzheimers disease Patients market in the global market. Below mentioned is the list of few companies engaged in the Alzheimers disease Patients Market.

The report also includes the profiles of key players in Alzheimers disease Patients Market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered financial information of last 3 years, key development in past five years.

  •   Allergan
  •   Eisai Co., Ltd.
  •   Novartis AG
  •   DAICHI SANKYO COMPANY LIMITED
  •   Merz Pharma
  •   Pfizer, Inc.
  •   Johnson and Johnson Services, Inc.
  •   H. Lundbeck A/S
  •   Biogen
  •   AstraZeneca

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Alzheimers Disease Patients Market - By Onset Type
1.3.2 Alzheimers Disease Patients Market - By Drug Class
1.3.3 Alzheimers Disease Patients Market - By Distribution Channel
1.3.4 Alzheimers Disease Patients Market - By Region
1.3.4.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. ALZHEIMER'S DISEASE PATIENTS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS

5. ALZHEIMER'S DISEASE PATIENTS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. ALZHEIMER'S DISEASE PATIENTS MARKET - GLOBAL MARKET ANALYSIS
6.1. ALZHEIMER'S DISEASE PATIENTS - GLOBAL MARKET OVERVIEW
6.2. ALZHEIMER'S DISEASE PATIENTS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE

7. ALZHEIMER'S DISEASE PATIENTS MARKET - REVENUE AND FORECASTS TO 2028 - ONSET TYPE
7.1. OVERVIEW
7.2. ONSET TYPE MARKET FORECASTS AND ANALYSIS
7.3. LATE ONSET DISEASE
7.3.1. Overview
7.3.2. Late onset disease Market Forecast and Analysis
7.4. EARLY ONSET DISEASE
7.4.1. Overview
7.4.2. Early Onset Disease Market Forecast and Analysis
8. ALZHEIMER'S DISEASE PATIENTS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
8.1. OVERVIEW
8.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
8.3. CHOLINERGIC
8.3.1. Overview
8.3.2. Cholinergic Market Forecast and Analysis
8.4. MEMANTINE
8.4.1. Overview
8.4.2. Memantine Market Forecast and Analysis
8.5. COMBINED DRUG
8.5.1. Overview
8.5.2. Combined Drug Market Forecast and Analysis
8.6. ACHE INHIBITORS
8.6.1. Overview
8.6.2. AChE inhibitors Market Forecast and Analysis
8.7. IMMUNOGLOBULINS
8.7.1. Overview
8.7.2. Immunoglobulins Market Forecast and Analysis
9. ALZHEIMER'S DISEASE PATIENTS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACY
9.3.1. Overview
9.3.2. Hospital Pharmacy Market Forecast and Analysis
9.4. RETAIL PHARMACY
9.4.1. Overview
9.4.2. Retail Pharmacy Market Forecast and Analysis
9.5. ONLINE SALES
9.5.1. Overview
9.5.2. Online Sales Market Forecast and Analysis

10. ALZHEIMER'S DISEASE PATIENTS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Alzheimers Disease Patients Market Overview
10.1.2 North America Alzheimers Disease Patients Market Forecasts and Analysis
10.1.3 North America Alzheimers Disease Patients Market Forecasts and Analysis - By Onset Type
10.1.4 North America Alzheimers Disease Patients Market Forecasts and Analysis - By Drug Class
10.1.5 North America Alzheimers Disease Patients Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Alzheimers Disease Patients Market Forecasts and Analysis - By Countries
10.1.6.1 United States Alzheimers Disease Patients Market
10.1.6.1.1 United States Alzheimers Disease Patients Market by Onset Type
10.1.6.1.2 United States Alzheimers Disease Patients Market by Drug Class
10.1.6.1.3 United States Alzheimers Disease Patients Market by Distribution Channel
10.1.6.2 Canada Alzheimers Disease Patients Market
10.1.6.2.1 Canada Alzheimers Disease Patients Market by Onset Type
10.1.6.2.2 Canada Alzheimers Disease Patients Market by Drug Class
10.1.6.2.3 Canada Alzheimers Disease Patients Market by Distribution Channel
10.1.6.3 Mexico Alzheimers Disease Patients Market
10.1.6.3.1 Mexico Alzheimers Disease Patients Market by Onset Type
10.1.6.3.2 Mexico Alzheimers Disease Patients Market by Drug Class
10.1.6.3.3 Mexico Alzheimers Disease Patients Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Alzheimers Disease Patients Market Overview
10.2.2 Europe Alzheimers Disease Patients Market Forecasts and Analysis
10.2.3 Europe Alzheimers Disease Patients Market Forecasts and Analysis - By Onset Type
10.2.4 Europe Alzheimers Disease Patients Market Forecasts and Analysis - By Drug Class
10.2.5 Europe Alzheimers Disease Patients Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Alzheimers Disease Patients Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Alzheimers Disease Patients Market
10.2.6.1.1 Germany Alzheimers Disease Patients Market by Onset Type
10.2.6.1.2 Germany Alzheimers Disease Patients Market by Drug Class
10.2.6.1.3 Germany Alzheimers Disease Patients Market by Distribution Channel
10.2.6.2 France Alzheimers Disease Patients Market
10.2.6.2.1 France Alzheimers Disease Patients Market by Onset Type
10.2.6.2.2 France Alzheimers Disease Patients Market by Drug Class
10.2.6.2.3 France Alzheimers Disease Patients Market by Distribution Channel
10.2.6.3 Italy Alzheimers Disease Patients Market
10.2.6.3.1 Italy Alzheimers Disease Patients Market by Onset Type
10.2.6.3.2 Italy Alzheimers Disease Patients Market by Drug Class
10.2.6.3.3 Italy Alzheimers Disease Patients Market by Distribution Channel
10.2.6.4 Spain Alzheimers Disease Patients Market
10.2.6.4.1 Spain Alzheimers Disease Patients Market by Onset Type
10.2.6.4.2 Spain Alzheimers Disease Patients Market by Drug Class
10.2.6.4.3 Spain Alzheimers Disease Patients Market by Distribution Channel
10.2.6.5 United Kingdom Alzheimers Disease Patients Market
10.2.6.5.1 United Kingdom Alzheimers Disease Patients Market by Onset Type
10.2.6.5.2 United Kingdom Alzheimers Disease Patients Market by Drug Class
10.2.6.5.3 United Kingdom Alzheimers Disease Patients Market by Distribution Channel
10.2.6.6 Rest of Europe Alzheimers Disease Patients Market
10.2.6.6.1 Rest of Europe Alzheimers Disease Patients Market by Onset Type
10.2.6.6.2 Rest of Europe Alzheimers Disease Patients Market by Drug Class
10.2.6.6.3 Rest of Europe Alzheimers Disease Patients Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Alzheimers Disease Patients Market Overview
10.3.2 Asia-Pacific Alzheimers Disease Patients Market Forecasts and Analysis
10.3.3 Asia-Pacific Alzheimers Disease Patients Market Forecasts and Analysis - By Onset Type
10.3.4 Asia-Pacific Alzheimers Disease Patients Market Forecasts and Analysis - By Drug Class
10.3.5 Asia-Pacific Alzheimers Disease Patients Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Alzheimers Disease Patients Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Alzheimers Disease Patients Market
10.3.6.1.1 Australia Alzheimers Disease Patients Market by Onset Type
10.3.6.1.2 Australia Alzheimers Disease Patients Market by Drug Class
10.3.6.1.3 Australia Alzheimers Disease Patients Market by Distribution Channel
10.3.6.2 China Alzheimers Disease Patients Market
10.3.6.2.1 China Alzheimers Disease Patients Market by Onset Type
10.3.6.2.2 China Alzheimers Disease Patients Market by Drug Class
10.3.6.2.3 China Alzheimers Disease Patients Market by Distribution Channel
10.3.6.3 India Alzheimers Disease Patients Market
10.3.6.3.1 India Alzheimers Disease Patients Market by Onset Type
10.3.6.3.2 India Alzheimers Disease Patients Market by Drug Class
10.3.6.3.3 India Alzheimers Disease Patients Market by Distribution Channel
10.3.6.4 Japan Alzheimers Disease Patients Market
10.3.6.4.1 Japan Alzheimers Disease Patients Market by Onset Type
10.3.6.4.2 Japan Alzheimers Disease Patients Market by Drug Class
10.3.6.4.3 Japan Alzheimers Disease Patients Market by Distribution Channel
10.3.6.5 South Korea Alzheimers Disease Patients Market
10.3.6.5.1 South Korea Alzheimers Disease Patients Market by Onset Type
10.3.6.5.2 South Korea Alzheimers Disease Patients Market by Drug Class
10.3.6.5.3 South Korea Alzheimers Disease Patients Market by Distribution Channel
10.3.6.6 Rest of Asia-Pacific Alzheimers Disease Patients Market
10.3.6.6.1 Rest of Asia-Pacific Alzheimers Disease Patients Market by Onset Type
10.3.6.6.2 Rest of Asia-Pacific Alzheimers Disease Patients Market by Drug Class
10.3.6.6.3 Rest of Asia-Pacific Alzheimers Disease Patients Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Alzheimers Disease Patients Market Overview
10.4.2 Middle East and Africa Alzheimers Disease Patients Market Forecasts and Analysis
10.4.3 Middle East and Africa Alzheimers Disease Patients Market Forecasts and Analysis - By Onset Type
10.4.4 Middle East and Africa Alzheimers Disease Patients Market Forecasts and Analysis - By Drug Class
10.4.5 Middle East and Africa Alzheimers Disease Patients Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Alzheimers Disease Patients Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Alzheimers Disease Patients Market
10.4.6.1.1 South Africa Alzheimers Disease Patients Market by Onset Type
10.4.6.1.2 South Africa Alzheimers Disease Patients Market by Drug Class
10.4.6.1.3 South Africa Alzheimers Disease Patients Market by Distribution Channel
10.4.6.2 Saudi Arabia Alzheimers Disease Patients Market
10.4.6.2.1 Saudi Arabia Alzheimers Disease Patients Market by Onset Type
10.4.6.2.2 Saudi Arabia Alzheimers Disease Patients Market by Drug Class
10.4.6.2.3 Saudi Arabia Alzheimers Disease Patients Market by Distribution Channel
10.4.6.3 U.A.E Alzheimers Disease Patients Market
10.4.6.3.1 U.A.E Alzheimers Disease Patients Market by Onset Type
10.4.6.3.2 U.A.E Alzheimers Disease Patients Market by Drug Class
10.4.6.3.3 U.A.E Alzheimers Disease Patients Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Alzheimers Disease Patients Market
10.4.6.4.1 Rest of Middle East and Africa Alzheimers Disease Patients Market by Onset Type
10.4.6.4.2 Rest of Middle East and Africa Alzheimers Disease Patients Market by Drug Class
10.4.6.4.3 Rest of Middle East and Africa Alzheimers Disease Patients Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Alzheimers Disease Patients Market Overview
10.5.2 South and Central America Alzheimers Disease Patients Market Forecasts and Analysis
10.5.3 South and Central America Alzheimers Disease Patients Market Forecasts and Analysis - By Onset Type
10.5.4 South and Central America Alzheimers Disease Patients Market Forecasts and Analysis - By Drug Class
10.5.5 South and Central America Alzheimers Disease Patients Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Alzheimers Disease Patients Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Alzheimers Disease Patients Market
10.5.6.1.1 Brazil Alzheimers Disease Patients Market by Onset Type
10.5.6.1.2 Brazil Alzheimers Disease Patients Market by Drug Class
10.5.6.1.3 Brazil Alzheimers Disease Patients Market by Distribution Channel
10.5.6.2 Argentina Alzheimers Disease Patients Market
10.5.6.2.1 Argentina Alzheimers Disease Patients Market by Onset Type
10.5.6.2.2 Argentina Alzheimers Disease Patients Market by Drug Class
10.5.6.2.3 Argentina Alzheimers Disease Patients Market by Distribution Channel
10.5.6.3 Rest of South and Central America Alzheimers Disease Patients Market
10.5.6.3.1 Rest of South and Central America Alzheimers Disease Patients Market by Onset Type
10.5.6.3.2 Rest of South and Central America Alzheimers Disease Patients Market by Drug Class
10.5.6.3.3 Rest of South and Central America Alzheimers Disease Patients Market by Distribution Channel

11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

12. ALZHEIMER'S DISEASE PATIENTS MARKET, KEY COMPANY PROFILES
12.1. ALLERGAN
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. EISAI CO., LTD
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. NOVARTIS AG
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. DAIICHI SANKYO COMPANY LIMITED
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. MERZ PHARMA
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. PFIZER INC
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. JOHNSON AND JOHNSON SERVICES, INC
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. H. LUNDBECK A/S
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. BIOGEN
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. ASTRAZENECA
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
12.11. F. HOFFMANN-LA ROCHE LTD
12.11.1. Key Facts
12.11.2. Business Description
12.11.3. Products and Services
12.11.4. Financial Overview
12.11.5. SWOT Analysis
12.11.6. Key Developments

13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Allergan
2. Eisai Co., Ltd
3. Novartis AG
4. DAIICHI SANKYO COMPANY LIMITED
5. Merz Pharma
6. Pfizer Inc
7. Johnson and Johnson Services, Inc
8. H. Lundbeck A/S
9. Biogen
10. AstraZeneca
11. F. Hoffmann-La Roche Ltd
TIPRE00019571
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking